Autolus Therapeutics

AUTL | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.94

$0 (0.00%)

At close: Sep 21, 2026, 4:00 PM ET

$1.97

+$0.03 (+1.55%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Aug 25, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $516.32M

1D Range

1.93 1.96

52W Range

1.18 2.58

Valuation (TTM)

PE -1.83

PB 6.90

EV/EBITDA -1.80

Valuation (NTM)

Forward PE N/A

Forward PEG 0.09

Price Target $8.87

Cash Flow

FCF Yield -46.0%

SBC Adj. FCF Yield -49.0%

SBC Impact -6.5%

Margins

Gross Margin 15.7%

Operating Margin -210.8%

FCF Margin -202.3%

Growth (CAGR)

Revenue 3Y | 5Y 150.3% | 108.2%

Dil EPS 3Y | 5Y 4.9% | 16.5%

FCF 3Y | 5Y -16.1% | -21.0%

Returns

ROA -56.8%

ROE -178.6%

ROIC -57.5%

Financial Health

Net Cash

$201.63M

Current Ratio 4.89

Interest Coverage -5.25

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes s...

Sector Healthcare

Industry Biotechnology

Employees 752

IPO Date Jun 21, 2018

Website www.autolus.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+312.37%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞